Reveromycin A (Rev.A) is an inhibitor of epidermal growth factor-dependent cell growth that is produced from the culture broth of an actinomycete strain. Rev.A was assessed for its ability to regulate antigen (Ag) presentation by A20-HL B lymphoma cells bearing trinitrophenyl (TNP)-specific surface IgM (sIgM) to cloned T cells specific for OVA323-339/I-Ad. Rev.A-treatment inhibited the presentation of Ag internalized via sIgM, but not of Ag via fluidphase pinocytosis. Rev.A-treatment decreased protein synthesis, but a similar decrease in protein synthesis by cycloheximide induced much less inhibition of sIgM-mediated Ag presentation. Rev.A-treatment decreased the rate of re-expression of sIgM in A20-HL cells, the amount of Ag internalized via sIgM during 3 hours of incubation, and the generation of antigenic peptides from TNP-OVA internalized via sIgM. Rev.A-treatment was suggested to affect intracellular trafficking from early endosomes into late endocytic compartments of Ag internalized via sIgM. Rev.A might provide a useful tool for studying intracellular transport of Ag, especially Ag internalized via sIgM.
phase pinocytosis. Rev.A-treatment decreased protein synthesis, but a similar decrease in protein synthesis by cycloheximide induced much less inhibition of sIgM-mediated Ag presentation. Rev.A-treatment decreased the rate of re-expression of sIgM in A20-HL cells, the amount of Ag internalized via sIgM during 3 hours of incubation, and the generation of antigenic peptides from TNP-OVA internalized via sIgM. Rev.A-treatment was suggested to affect intracellular trafficking from early endosomes into late endocytic compartments of Ag internalized via sIgM. Rev.A might provide a useful tool for studying intracellular transport of Ag, especially Ag internalized via sIgM. into A20-HL cells via BCR, which was TNP-specific sIgM in these cells. sIgM expression on the Rev.A-treated A20-HL cells was decreased relative to untreated A20-HL cells, but indistinguishable from that on cells treated with CHX ( Fig. 2-A) . Internalization of FITC-labeled TNP-OVA via BCR into Rev.A-treated A20-HL cells appeared to be slightly less than that observed into the CHX-treated cells (Fig. 2-B-I ), although the detectable amount was small. To confirm these findings, FITC-anti-mouse IgM goat IgG F(ab')2 was used as a model for TNP-OVA. A20-HL cells were incubated with FITC-anti-IgM IgG F(ab')2 for 20 or after stripping the remaining FITC-anti-IgM IgG F(ab')2 on the cell surface using treatment with acidic buffer. As shown in Fig. 2-B and LAMP-1, suggesting that traffic from the early endosomes into the late endosomes was inhibited. This inhibition was Rev.A-dose dependent. When A20-HL cells Fig. 5-B ).
An acidic pH was required for the generation of antigenic peptides from protein Ag in the endocytic compartments36). Intracellular pH was also examined in Pixel total (x 104) 
